Advanced

Osteoporosis following heart transplantation and immunosuppressive therapy

Löfdahl, Eveline LU and Rådegran, Göran LU (2017) In Transplantation Reviews
Abstract

Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current... (More)

Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current knowledge on bone strength impairment after HT and concomitant immunosuppressive therapy.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Transplantation Reviews
publisher
Elsevier
external identifiers
  • scopus:85028612208
  • wos:000416196900002
ISSN
0955-470X
DOI
10.1016/j.trre.2017.08.002
language
English
LU publication?
yes
id
793a2f50-9aa5-4fa7-94f1-151d6493303a
date added to LUP
2017-10-04 16:38:00
date last changed
2018-01-16 13:20:49
@article{793a2f50-9aa5-4fa7-94f1-151d6493303a,
  abstract     = {<p>Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current knowledge on bone strength impairment after HT and concomitant immunosuppressive therapy.</p>},
  author       = {Löfdahl, Eveline and Rådegran, Göran},
  issn         = {0955-470X},
  language     = {eng},
  month        = {08},
  publisher    = {Elsevier},
  series       = {Transplantation Reviews},
  title        = {Osteoporosis following heart transplantation and immunosuppressive therapy},
  url          = {http://dx.doi.org/10.1016/j.trre.2017.08.002},
  year         = {2017},
}